AstraZeneca Pharma India Ltd. — Board/Management Information 2024

Feb 20, 2024

==> picture [452 x 78] intentionally omitted <==

February 20, 2024

The Manager- Listing BSE Limited Corporate Relationship Dept., 5[th] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai – 400 001

The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, 5[th] Floor, Plot No. C/1, G - Block Bandra –Kurla Complex, Bandra (E), Mumbai – 400 051

Dear Sir(s),

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) – Regulations, 2015 Change in role of Senior Management Personnel

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you on the change in role of Mr. Amit Bhakri, currently the Business Unit Director - Biopharmaceutical Business Unit. He will be transitioning from the said role with effect from close of business hours on March 31, 2024, as he takes up another responsibility within AstraZeneca group.

Further, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Ayush Kumar Agarwal as Business Unit Director- Biopharmaceutical Business Unit with effect from April 1, 2024. Currently he is the Director – Commercial excellence and will continue leading the same in the interim till a replacement for the said position is filled.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached herewith as Annexure – A .

Kindly take the above information on record.

For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA A RAMA Date: 2024.02.20 08:54:34 +05'30' Manasa. R Company Secretary

==> picture [453 x 64] intentionally omitted <==

==> picture [452 x 78] intentionally omitted <==

Annexure - A

Sl.	Particulars	Details for change in role of Mr. Ayush Kumar Agarwal
No
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. Ayush Kumar Agarwal as Business Unit Director- Biopharmaceutical Business
2	Date of appointment/ cessation (as applicable) and term of appointment	Effective April 1, 2024 Term of appointment – Full – time employement
3	Brief Profile	Mr. Ayush Kumar Agarwal is a Post‐Graduate in Marketing Management with over 28 years of rich industry experience. He has been with AstraZeneca since 2004 when he joined in India as Area Business Manager - Specialty Care. Over last 16 years, he has held multiple sales, marketing, and leadership positions in AstraZeneca. Under Ayush's leadership, Fasenra has grown by 111% and Forxiga by 52% in public channel in 2023. He has guided SFE team in simplifying and automating dashboards. He has paved way for multiple new launches and line extensions in the country like Enhertu, Koselugo and many more bringing India MC closer to reaching the Bold Ambition 2025. He has held some critical positions during his stint with AstraZeneca such as - Director Frontier Markets, Asia Area Chief of Staff, Interim Asia Area Commercial Director – BBU. Currently, he is the Director‐Commercial Excellence.
4	Disclosure of relationships between directors	Not Applicable

==> picture [453 x 64] intentionally omitted <==